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Abstract: The effect of five approved tumour necrosis factor inhibitors (TNFi: infliximab, etanercept,
adalimumab, certolizumab, and golimumab) on joint destruction in rheumatoid arthritis (RA) have
been compared versus methotrexate (MTX) in randomized controlled trials (RCTs) but have not
been compared directly to each other or to an otherwise untreated placebo control. The present
analysis compares effects of standard doses, high doses, and low doses of TNFis on radiographic
joint destruction in RA and relate these effects to MTX and placebo by means of a Bayesian network
meta-analysis. We identified 31 RCTs of the effect of TNFis on joint destruction and 5 RCTs with
controls, which indirectly could link otherwise untreated placebo controls to the TNFi treatments in
the network. The previously untested comparison with placebo was performed to estimate not only
the effect relative to another drug, but also the absolute attainable effect. Compared to placebo there
was a highly significant inhibitory effect on joint destruction of infliximab, etanercept, adalimumab,
certolizumab, and golimumab, which was about 0.9% per year as monotherapy and about 1.2% per
year when combined with MTX. Although significantly better than MTX and placebo, golimumab
seemed inferior to the remaining TNFis. There was no difference between original reference drugs
(Remicade, Enbrel) and the almost identical copy drugs (biosimilars).
Keywords: rheumatoid arthritis; tumor necrosis factor (TNF) inhibitors; joint destruction; randomized
controlled trial; network meta-analysis
1. Introduction
Rheumatoid arthritis (RA) is thought to be generated by an autoimmune response in which
the innate immune system (dendritic cells, macrophages) presents antigens to the adaptive immune
system (T-cells, B-cells) initiating an inflammatory cascade, which enhances local inflammation of the
synovial membrane (synovitis) and results in damage to the cartilage and bone components of the
joints [1]. Over time, there is a strong association between the cumulated degree of synovitis and the
development of joint damage [2–4]. Tumour necrosis factor (TNF) is a cytokine with an important role
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in this process, but the exact mechanism is still controversial [1]. The first TNF inhibitor (TNFi) shown
to be effective in the treatment of RA is a chimeric monoclonal murine/human antibody to TNFα (cA2
= infliximab) directly inhibiting the TNF molecule [5], whereas the second is a genetically engineered
TNF receptor blocker (etanercept) [6].
Three succeeding TNFis (adalimumab, certolizumab, and golimumab) are antibodies like
infliximab, but are purely human. The original reference drugs are Remicade (infliximab), Enbrel
(etanercept), Humira (adalimumab), Cimzia (certolizumab), and Simponi (golimumab). A detailed
description of the structure of all five TNFis have recently been reviewed [1]. No studies have directly
compared the efficacies of these inhibitors, but indirect evidence indicate that they are similar [7,8],
although the effect of the defined standard dose of golimumab may be inferior [8]. This indirect
evidence is based on randomized controlled trials (RCTs) comparing a TNFi in combination with the
conventional disease modifying anti-rheumatic drug (DMARD), methotrexate (MTX), versus placebo
plus MTX, or TNFi mono-therapy versus MTX mono-therapy. No RCT has compared a TNFi to an
otherwise untreated placebo control.
In the recent years, statistical software has matured to combine such indirect comparisons into
one integrated network analysis, based on which treatments can be ranked, and to include different
doses of the target drugs in the analysis [9]. A PubMed search (20 April 2019) with the search term
“meta-analysis and rheumatoid arthritis and TNF inhibitor” revealed 135 articles of which only 2 [10,11]
are network meta-analyses, which exclusively compare the efficacies of the 5 known TNFis using the
American College of Rheumatology improvement criteria (ACR 20, 50, and 70) and health assessment
questionnaire (HAQ) scores as primary outcome measures. One network meta-analysis of 26 trials
found that TNFi combined with MTX was superior to either MTX or TNFi alone. Increasing doses did
not improve the efficacy [10]. Another analysis of 16 trials of MTX non-responders found that all TNFis
showed considerably improved efficacy over placebo plus MTX but etanercept appeared superior
to infliximab and golimumab, and certolizumab to infliximab and adalimumab [10]. One reason
could be that the defined standard doses are not equivalent. Subsequently, a significant fraction of
additional studies including studies of biosimilars, i.e., copy-products of the original reference drugs
have appeared. As costs are one of the main obstacles for the use of TNFis, especially in low-income
countries, a definition of the relative efficacy of the less expensive biosimilars is important.
The primary purpose of the present meta-analysis of randomized controlled trials (RCTs) was
in one network to compare the standard doses of the five TNFis (reference drugs and biosimilars)
combined with MTX to MTX mono-therapy (the primary comparator) and to TNFi mono-therapy,
and for the first time also to an otherwise untreated placebo control, which was included in the
network to give an estimation of the absolute inhibitory ability of the TNFis (assuming that placebo
has no inhibitory effect). In contrast to the previous meta-analyses [10,11] we used radiographically
estimated joint destruction [7,8,12] as the primary outcome. The secondary purpose was to relate
TNFi doses below and above the standard doses to the standard doses and to MTX mono-therapy and
placebo. The reference TNFis, as well as recent biosimilars, are included in the analysis. The analysis is
reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
incorporating network meta-analyses (PRISMA extension statement) [13].
2. Results
2.1. Result of the Search
The search resulted in 3184 articles. We organised the search in a Word document including all
headlines and abstracts. To avoid overlooking studies with radiographic evaluation we searched the
text for the term “radio” (which covers radiologic(al), radiology, radiograph(ic(al))) (1621 selections)
and the term “X-ray” (131 selections). During this search, we excluded 2922 studies. We then read
the 262 remaining abstracts in detail and excluded a further 111. Thus, 151 studies were included for
retrieving full-length articles. From this pool of 151 articles we identified 36 RCTs (Figure 1), 31 TNFi
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RCTs and 5 RCTs, which could link an otherwise untreated placebo group to the network, 1 study
of MTX vs. placebo, 3 studies of sulfasalazine vs. placebo, and 1 study of MTX vs. sulfasalazine.
These 36 RCTs were published in 35 articles [14–48].
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2.2. Description of Included Studies
Baseline characteristics are shown in Table 1. The number of patients in the studies varied from
24 to 1022 (Table 1, N column). The study duration varied from 24 weeks to 104 weeks (Table 1,
SD column). The mean duration of disease (RA) varied from 0.2 to 11 years (Table 1, DD column).
The mean age varied from 48.4 to 60.7 years (Table 1, Age column). The percentage of females varied
from 64% to 85.7% (Table 1, F% column). The percentage of rheumatoid factor positive patients varied
from 54.9% to 100% (Table 1, RF% column). The state of disease activity at baseline was reported by
all studies. Most studies reported swollen joint count (SJC), tender joint count (TJC), and erythrocyte
sedimentation rate (ESR) and/or C-reactive protein (CRP). These variables are included in the disease
activity score based on 28 joints or 44 joints (DAS28 score or DAS44 score). Two studies reported
DAS44 [17,25], which was converted to DAS28 as described in the methods section. In six studies with
no report of DAS28 [14–16,18,19,23] we could estimate a mean DAS28 from SJC, TJC, and CRP or ESR
as described in the methods section. Twenty-eight studies directly reported DAS28. Thus, a DAS28
value was available for all studies. DAS28 varied from 4.4 to 7.0 (Table 1, DAS28 column). The health
assessment questionnaire score varied from 1.0 to 1.8 (Table 1, HAQ column). The state of chronicity is
characterized by the radiographic score, which varied from 2 to 159 (Table 1, RS column).
Table 1. Baseline study characteristics.
Ref. TD/C GC. mg DIR RP IOC N SD,weeks
DD,
years
Age,
years F% RF% DAS28 HAQ RS
[14] Su/Pl 0.4 No IS Yes 73 52 0.5 51.3 64.0 66.7 5.6 1.4 2.0
[15] Su/Pl 1.3 No S No 137 24 6.6 58.9 72.5 81.5 6.8 1.1 57.6
[16] Mt/Pl 2.7 No S No 221 52 6.7 54.0 72.8 59.8 6.4 1.3 24.1
[17] Mt/Su 0.0 No IS No 95 52 1.2 51.0 72.5 68.5 5.5 1.3 7.2
[18] In/Mt 3.2 Yes IS Yes 135 54 10.5 52.5 80.5 80.5 6.7 1.8 80.5
[19] Et/Mt 2.8 o IS Yes 390 52 1.0 49.5 75.0 88.5 6.9 1.4 12.1
[20] Su/Pl 0.0 No IS Yes 83 52 0.5 57.1 75.0 56.0 5.2 1.2 3.9
[21] Et/Mt 3.1 Yes IS UC 424 52 6.6 53.1 78.0 73.0 5.6 1.4 32.2
[22] In/Mt 1.9 No S No 532 54 0.9 50.5 73.0 71.0 6.7 1.5 11.5
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Table 1. Cont.
Ref. TD/C GC. mg DIR RP IOC N SD,weeks
DD,
years
Age,
years F% RF% DAS28 HAQ RS
[23] Ad/Mt 2.6 Yes IS Yes 368 52 11.0 56.7 74.3 85.4 6.1 1.5 66.5
[24] In/Mt 2.5 Yes S No 24 54 1.5 53.3 75.5 100.0 5.3 1.4 18.0
[25] In/Mt 0.0 No S Yes 234 52 0.6 54.0 67.0 65.5 5.5 1.4 7.2
[26] Ad/Mt 2.2 No IS Yes 531 52 0.8 52.1 75.7 79.9 6.4 1.6 20.4
[27] Et/Mt 2.5 No S No 476 52 0.8 51.4 73.5 68.5 6.5 1.7 6.0
[28] Cz/Mt 1.7 Yes IS No 592 52 6.2 51.8 83.2 81.2 7.0 1.7 41.1
[29] Cz/Mt 2.8 Yes IS No 373 24 5.9 51.9 84.0 77.9 6.8 1.6 43.1
[30] In/In 3.4 Yes IS No 178 40 7.8 49.3 80.8 87.0 6.2 1.2 48.5
[31] Go/Mt 3.3 No IS No 280 52 3.5 48.4 84.1 81.5 5.1 1.6 20.1
[31] Go/Mt 4.8 Yes IS No 234 52 6.2 51.5 80.5 82.4 6.1 1.4 37.1
[32] Go/Mt 2.5 Yes IS Yes 165 24 8.8 50.8 84.0 79.9 5.6 1.0 56.1
[33] Ad/Mt 2.2 No IS No 1022 26 0.4 50.6 74.0 88.0 6.0 1.6 11.5
[34] Et/Et 4.4 Yes IS UC 62 52 9.2 60.7 80.0 81.4 4.8 1.0 159.9
[35] Et/Et 3.8 No IS No 63 104 10.9 60.6 85.7 75.0 4.4 1.4 54.0
[36] Go/Mt 2.5 Yes IS No 592 24 7.0 51.7 81.1 100.0 6.0 1.6 49.0
[37] Et/Mt 3.0 Yes S No 361 52 3.0 51.0 79.9 75.6 5.8 1.1 44.1
[38] Go/Mt 2.5 Yes IS Yes 206 24 8.7 52.7 81.1 NR 5.9 1.1 50.0
[39] In/Mt 1.6 No S No 112 26 0.1 53.3 68.7 54.9 4.3 1.4 7.6
[40] Ad/Mt 1.6 No IS No 331 26 0.3 54.0 81.3 84.4 6.6 1.2 13.7
[41] Cz/Su.Pl 3.6 Yes S No 114 24 5.8 55.4 77.2 89.5 6.3 1.2 46.1
[42] Cz/Mt 3.1 Yes S No 146 24 5.9 53.1 83.2 88.0 6.4 1.2 53.8
[43] Cz/Mt 0.9 No IS UC 315 24 0.3 49.2 81.0 96.2 5.5 1.1 5.6
[44] Ad/Mt 0.9 No IS Yes 173 52 0.2 55.2 66.0 72.0 5.6 1.1 4.4
[45] In/In 2.5 Yes IS UC 336 54 NR 50.0 82.7 73.5 5.9 1.6 66.6
[46] Cz/Mt 1.6 No IS No 691 52 0.3 50.8 77.9 96.8 6.8 1.7 7.9
[47] Et/Et 2.5 Yes IS Yes 478 52 6.1 51.9 84.3 78.6 6.5 1.5 41.1
[48] In/In 2.5 Yes S No 422 54 6.5 52.1 80.1 72.5 6.5 1.5 38.0
TD/C: testdrug/control; Ad: adalimumab; Cz: certolizumab; Et: etanercept; Go: golimumab; In: infliximab;
Mt: methotrexate; Pl: placebo; Su: sulfasalazine; GC: glucocorticoid (prednisolone equivalent); DIR: DMARD
inadequate response; RP: randomization procedure; IS: insufficiently described; S: sufficiently described; IOC:
incomplete outcome; UC: unclear; SD: study duration; DD: disease duration; F: female; RF: rheumatoid factor;
DAS28: disease activity score based on evaluation of 28 joints; HAQ: health assessment score; RS: total radiographic
joint score.
Glucocorticoid (GC) was not allowed in two studies [17,20]. In the remaining studies the mean GC
dose per patient varied from 0.4 mg to 4.8 mg (Table 1, GC column). One study directly reported the
mean GC intake in the treatment groups [34]. Three studies did not report the GC treatment interval
but did report the percentage of patients being treated with GC [21,40,43]. An estimated dose of 5 mg
of GC multiplied by the percentage of treated patients was imputed for these three studies. Six studies
only reported the interval of 0–10 mg of GC [32,36,39,45,47,48]. Assuming a median dose of 5 mg and
50% of the patients receiving GC, an estimated GC intake of 2.5 mg was imputed for these six studies.
The remaining studies reported both the interval of intake and the percentage of patient taking steroids.
The median GC dose of the interval multiplied by the percentage of treated patients was imputed for
these studies.
2.3. Risk of Bias in Included Studies
We estimated bias by means of the Cochrane risk of bias tool [49]. Based on the description of
the randomization procedure (Table 1, column RP) (sequence generation and concealed allocation),
11 studies featured sufficient description, and 25 studies insufficient description.
32 studies were double-blinded, whereas 4 studies were open studies [18,19,25,34], but the
radiographic scores were estimated blindly in all studies. All but 3 studies [20,39,44] were initiated by
pharmaceutical companies.
21 studies used the ‘intention to treat’ (ITT) principle with no use of data obtained during rescue
therapy (i.e., open-label administration of alternative drug when the allocated treatment is insufficient)
in the efficacy analyses, whereas 11 studies either used such data in the efficacy analyses or completely
excluded drop-outs without using the ITT principle. In four studies, the use of ITT was unclear. Thus,
there was no indication of incomplete outcome data (IOC) in 21 studies and indication of either obvious
or unclear incomplete outcome data in 15 studies (Table 1, column IOC)
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In 18 studies, the study populations had an inadequate response to previous MTX or other
DMARD (DIR), whereas 18 study populations did not (Table 1, column DIR).
2.4. Trial Network
The trial network (Figure 2) is quite sparse with few direct comparisons available. Each node
represents one treatment with shorthand labels, lines show direct comparisons in the included studies.
Node sizes are proportional to number of patients receiving the treatments, line thicknesses to
the number of studies with these comparisons. Treatments cluster according to active ingredient,
and each cluster is well-connected to MTX. Biosimilars are compared only to their respective reference
drugs, and Golimumab 130 mg combined with MTX (Go13Mt) to MTX only. Based on its high
degree centrality [50] and its status as standard treatment, we chose MTX as the comparator to avoid
uncertainty inflation due to network traversal. All fits showed satisfactory mixing and convergence
of chains.
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Figure 2. Network of treatments investigated in included studies. (Ad20x2Mt (adalimumab
20 mg/1 week plus MTX); AdMt (adalimumab 40 mg/2 weeks plus MTX); Ad (adalimumab
40 mg/2 weeks); Cz4Mt (certolizumab 400 mg/2 weeks plus MTX); Cz1Mt (certolizumab 100 mg/2 weeks
plus MTX); Cz2Mt (certolizumab 200 mg/2 weeks plus MTX); C 2 (certolizumab 200 mg/2 weeks);
Su (sulfasalazine); Pl (placebo); In20 t (infliximab 20 mg/kg/8 weeks plus MTX); In10Mt (infliximab
10 mg/kg/8 weeks plus MTX); In6Mt (infliximab 6 mg/kg/8 weeks plus MTX); In3Mt (infliximab
3 mg/kg/8 weeks plus MTX); SB2 (biosimilar infliximab); CTP (biosimilar infliximab); SB4 (biosimilar
etanercept); Et25Mt (etanercept 25 mg/1 week plus MTX); Et50Mt (etanercept 50 mg/1 week plus MTX);
Et50 (etanercept 50 mg/1 week); Et20 (etanercept 20 mg/1 week); Go5Mt (goli umab 50 mg/4 weeks
plus MTX); Go10 (golimumab 100 mg/4 weeks); Go10Mt (golimumab 100 mg/4 weeks plus MTX);
Go13Mt (golimumab 130 mg/4 weeks plus MTX)).
2.5. Treatment Effects
We perf rm d 6 adjusted meta-regression fit analyses f the 25 treatme ts (including placebo)
with each of the defined covariates individually-randomization procedure (dichotomous); incomplete
outcome assessment (dichotomous); glucocorticoid treatment (continuous); disease activity score
(continuous); health assessment score (continuous); total radiographic joint score, RS (continuous)
(Table 2) and one including four covariates (Table 3). All continuous covariates were mean-centred
and scaled to 1 standard deviation. Table 2 shows the unadjusted analysis and six regression analyses
with one covariate at a time. The random-effects models, generally, yielded substantially lower
DIC estimates than the corresponding fixed-effects models, suggesting superiority of the former.
Thus, only the random-effects models are shown. The results are shown as difference in annual percent
point between each of the investigated treatments, compared to MTX.
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Table 2. Random-effects regression analyses with one covariate at a time.
Treatment # Unadjusted DAS28 * HAQ * Baseline RS * Glucocorti-CoidDose *
Incomplete
Outcome
Randomi-Zation
Procedure
Coefficient — −0.0 (−0.2, 0.1) 0.0 (−0.1, 0.2) −0.3 (−0.4, 0.1) −0.1 (−0.2, 0.1) −0.1 (−0.3, 0.2) 0.2 (−0.1, 0.6)
Ad40 −0.1 (−0.8, 0.5) −0.1 (−0.8, 0.5) −0.1 (−0.8, 0.5) −0.2 (−0.8, 0.3) −0.2 (−0.8, 0.4) −0.1 (−0.8, 0.5) −0.4 (−1.1, 0.4)
Ad20x2Mt −0.4 (−0.8, 0.0) −0.4 (−0.8, 0.0) −0.4 (−0.8, 0.0) −0.3 (−0.6, 0.0) −0.4 (−0.8, 0.0) −0.3 (−0.8, 0.1) −0.6 (−1.2, −0.1)
Ad40Mt −0.5 (−0.7, −0.3) −0.5 (−0.7, −0.3) −0.5 (−0.7, 0.3) −0.6 (−0.8, 0.4) −0.5 (−0.8, 0.3) −0.5 (−0.7, 0.2) −0.7 (−1.2, −0.3)
Cz100Mt −0.2 (−0.9, 0.3) −0.2 (−0.8, 0.4) −0.3 (−0.9, 0.3) −0.3 (−0.8, 0.2) −0.3 (−0.9, 0.3) −0.2 (−0.9, 0.4) −0.4 (−1.2, 0.2)
Cz200 −1.1 (−2.1, −0.2) −1.1 (−2.1, −0.1) −1.1 (−2.1, 0.1) −1.3 (−2.1, 0.4) −1.1 (−2.1, 0.1) −1.1 (−2.1, 0.1) −1.1 (−2.1, −0.2)
Cz200Mt −0.5 (−0.7, −0.3) −0.4 (−0.7, −0.2) −0.5 (−0.8, 0.3) −0.6 (−0.8, 0.4) −0.5 (−0.8, 0.3) −0.5 (−0.7, 0.2) −0.7 (−1.1, −0.3)
Cz400Mt −0.5 (−0.9, −0.3) −0.5 (−0.8, −0.2) −0.6 (−0.9, 0.3) −0.6 (−0.9, 0.4) −0.6 (−0.9, 0.3) −0.5 (−0.9, 0.3) −0.8 (−1.2, −0.3)
Et20 −0.2 (−0.6, 0.1) −0.2 (−0.6, 0.1) −0.2 (−0.6, 0.1) −0.3 (−0.6, 0.0) −0.2 (−0.6, 0.1) −0.2 (−0.6, 0.2) −0.4 (−0.8, 0.0)
Et25Mt −0.5 (−1.1, 0.0) −0.5 (−1.1, 0.0) −0.6 (−1.2, 0.0) −0.7 (−1.2, 0.3) −0.5 (−1.1, 0.0) −0.5 (−1.2, 0.1) −0.6 (−1.3, −0.0)
Et50 −0.5 (−0.8, −0.2) −0.5 (−0.8, −0.2) −0.5 (−0.8, 0.2) −0.6 (−0.9, 0.3) −0.4 (−0.8, 0.2) −0.4 (−0.8, 0.1) −0.6 (−1.0, −0.2)
SB4Et50Mt −0.7 (−1.2, −0.2) −0.7 (−1.2, −0.2) −0.7 (−1.3, −0.2) −0.9 (−1.2, −0.5) −0.7 (−1.2, 0.2) −0.7 (−1.2, −0.1) −0.8 (−1.3, −0.3)
Et50Mt −0.6 (−0.9, −0.3) −0.6 (−0.9, −0.3) −0.7 (−1.0, −0.3) −0.8 (−1.1, −0.5) −0.6 (−0.9, 0.3) −0.6 (−0.9, −0.3) −0.7 (−1.1, −0.4)
Go100 −0.1 (−0.4, 0.2) −0.1 (−0.5, 0.2) −0.1 (−0.5, 0.2) −0.2 (−0.4, 0.1) −0.0 (−0.4, 0.3) −0.1 (−0.4, 0.2) −0.4 (−0.9, 0.1)
Go50Mt −0.2 (−0.5, 0.1) −0.2 (−0.5, 0.1) −0.2 (−0.5, 0.1) −0.2 (−0.4, 0.0) −0.1 (−0.5, 0.2) −0.2 (−0.5, 0.1) −0.4 (−0.9, 0.0)
Go100Mt −0.4 (−0.6, −0.1) −0.4 (−0.7, −0.1) −0.4 (−0.6, −0.1) −0.4 (−0.6, −0.2) −0.3 (−0.6, 0.0) −0.3 (−0.6, −0.1) −0.6 (−1.1, −0.1)
Go130Mt −0.5 (−0.9, −0.1) −0.5 (−1.0, −0.1) −0.6 (−1.1, −0.1) −0.4 (−0.8, −0.1) −0.5 (−1.0, 0.1) −0.5 (−1.0, −0.1) −0.7 (−1.3, −0.2)
SB2In3Mt −0.9 (−1.4, −0.4) −0.9 (−1.4, −0.4) −0.9 (−1.5, −0.4) −1.0 (−1.4, −0.7) −0.9 (−1.4, 0.4) −0.9 (−1.4, −0.4) −0.9 (−1.4, −0.4)
CTPIn3Mt −0.8 (−1.3, −0.3) −0.8 (−1.4, −0.3) −0.8 (−1.4, −0.3) −0.9 (−1.4, −0.5) −0.8 (−1.4, 0.3) −0.8 (−1.4, −0.2) −0.8 (−1.4, −0.3)
In3Mt −0.9 (−1.2, −0.6) −0.9 (−1.2, −0.6) −0.9 (−1.2, −0.6) −1.0 (−1.3, −0.8) −0.9 (−1.2, 0.6) −0.9 (−1.2, −0.6) −0.9 (−1.2, −0.6)
In6Mt −0.8 (−1.2, −0.5) −0.8 (−1.2, −0.5) −0.9 (−1.2, −0.5) −0.9 (−1.2, −0.7) −0.9 (−1.2, 0.5) −0.8 (−1.2, −0.5) −0.9 (−1.2, −0.5)
In10Mt −1.0 (−1.4, −0.7) −1.0 (−1.4, −0.7) −1.1 (−1.5, −0.7) −1.1 (−1.4, −0.8) −1.1 (−1.5, 0.7) −1.0 (−1.4, −0.6) −1.1 (−1.5, −0.7)
In20Mt −1.3 (−1.8, −0.9) −1.3 (−1.8, −0.9) −1.4 (−1.9, −0.9) −1.4 (−1.8, −1.0) −1.3 (−1.8, 0.9) −1.3 (−1.8, −0.8) −1.4 (−1.9, −0.9)
Sulfasalazin −0.7 (−1.2, −0.1) −0.7 (−1.2, −0.1) −0.7 (−1.2, −0.0) −0.8 (−1.3, −0.3) −0.7 (−1.3, 0.1) −0.7 (−1.2, −0.1) −0.7 (−1.3, −0.1)
Placebo 0.4 (−0.0, 0.8) 0.4 (−0.0, 0.8) 0.4 (−0.0, 0.8) 0.2 (−0.1, 0.6) 0.4 (−0.0, 0.8) 0.4 (−0.1, 0.8) 0.4 (−0.1, 0.8)
σ ** 0.2 (0.1, 0.3) 0.2 (0.1, 0.3) 0.2 (0.1, 0.3) 0.1 (0.0, 0.2) 0.2 (0.1, 0.3) 0.2 (0.1, 0.3) 0.2 (0.1, 0.3)
Dbar † −117.4 −117.4 −119.7 −119.5 −117.4 −118.2 −119.1
DIC −43.0 −42.1 −44.0 −50.4 −42.3 −42.6 −43.4
pD 74.3 75.3 75.7 69.0 75.0 75.5 75.8
#: all treatment compared to MTX; * Scaled to 0 mean and 1 standard deviation; **: heterogeneity; † Compared to 93 data points from 36 studies; Ad: adalimumab; Cz: certolizumab;
Et: etanercept; Go: golimumab; In: infliximab; Mt: methotrexate; SB2 (infliximab biosimilar), CTP (infliximab biosimilar) and SB4 (etanercept biosimilar) are biosimilar products.
Dbar: posterior mean residual deviance; DIC: deviance information criterion; pD: estimated effective number of parameters.
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Table 3. Difference in annual percent point progression between each of the investigated treatments,
compared to methotrexate. Positive values favour methotrexate. Values are median of posterior
distribution (95% CrI).
Treatment # Four-Covariate Metaregression RS Covariate Metaregression Unadjusted Model
Random Eff. Random Eff. Random Eff.
DAS28* 0.0 (−0.1, 0.1) - -
Incomplete outcome 0.1 (−0.1, 0.3) - -
Glucocorticoid dose* 0.1 (−0.1, 0.3) - -
Relative base RS* −0.3 (−0.5, −0.2) −0.3 (−0.4, 0.1) -
Ad40 −0.2 (−0.8, 0.3) −0.2 (−0.8, 0.3) −0.1 (−0.8, 0.5)
Ad20x2Mt −0.3 (−0.7, 0.0) −0.3 (−0.6, 0.0) −0.4 (−0.8, 0.0)
Ad40Mt −0.6 (−0.9, −0.4) −0.6 (−0.8, 0.4) −0.5 (−0.7, −0.3)
Cz100Mt −0.3 (−0.9, 0.2) −0.3 (−0.8, 0.2) −0.2 (−0.9, 0.3)
Cz200 −1.3 (−2.2, −0.4) −1.3 (−2.1, 0.4) −1.1 (−2.1, −0.1)
Cz200Mt −0.6 (−0.8, −0.4) −0.6 (−0.8, 0.4) −0.5 (−0.7, −0.3)
Cz400Mt −0.6 (−0.9, −0.4) −0.6 (−0.9, 0.4) −0.5 (−0.8, −0.3)
Et20 −0.5 (−0.9, −0.1) −0.3 (−0.6, 0.0) −0.2 (−0.6, 0.1)
Et25Mt −0.9 (−1.4, −0.3) −0.7 (−1.2, 0.3) −0.5 (−1.1, 0.0)
Et50 −0.8 (−1.1, −0.4) −0.6 (−0.9, 0.3) −0.5 (−0.8, −0.2)
SB4Et50Mt −1.0 (−1.4, −0.6) −0.9 (−1.2, −0.5) −0.7 (−1.2, −0.2)
Et50Mt −0.9 (−1.3, −0.6) −0.8 (−1.1, −0.5) −0.6 (−0.9, −0.3)
Go100 −0.4 (−0.8, 0.0) −0.2 (−0.4, 0.1) −0.1 (−0.4, 0.2)
Go50Mt −0.4 (−0.8, −0.0) −0.2 (−0.4, 0.0) −0.2 (−0.5, 0.1)
Go100Mt −0.6 (−0.9, −0.2) −0.4 (−0.6, −0.2) −0.4 (−0.6, −0.1)
Go130Mt −0.4 (−0.7, −0.1) −0.4 (−0.8, −0.1) −0.5 (−1.0, −0.1)
SB2In3Mt −1.0 (−1.4, −0.6) −1.0 (−1.4, −0.7) −0.9 (−1.4, −0.4)
CTPIn3Mt −0.9 (−1.4, −0.5) −0.9 (−1.4, −0.5) −0.8 (−1.3, −0.3)
In3Mt −1.0 (−1.3, −0.7) −1.0 (−1.3, −0.8) −0.9 (−1.2, −0.6)
In6Mt −0.9 (−1.3, −0.7) −0.9 (−1.2, −0.7) −0.8 (−1.2, −0.5)
In10Mt −1.1 (−1.5, −0.8) −1.1 (−1.4, −0.8) −1.0 (−1.4, −0.7)
In20Mt −1.4 (−1.8, −1.0) −1.4 (−1.8, −1.0) −1.3 (−1.8, −0.9)
Sulfasalazin −0.8 (−1.4, −0.3) −0.8 (−1.3, −0.3) −0.7 (−1.2, −0.1)
Placebo 0.2 (−0.2, 0.5) 0.2 (−0.1, 0.6) 0.4 (−0.0, 0.8)
σ ** 0.1 (0.0, 0.2) 0.1 (0.0, 0.2) 0.2 (0.1, 0.3)
Dbar † −119.4 −119.5 −117.4
DIC −47.6 −50.4 −43.0
pD 71.8 69.0 74.3
Effect of standard TNFi doses are in bold. # All treatment compared to MTX; * Scaled to 0 mean and 1 standard
deviation; ** Heterogeneity; † Compared to 93 data points from 36 studies. Ad: adalimumab; Cz: certolizumab;
Et: etanercept; Go: golimumab; In: infliximab; Mt: methotrexate; SB2 (infliximab), CTP (infliximab), and SB4
(etanercept) are biosimilar products. Dbar: posterior mean residual deviance; DIC: deviance information criterion;
pD: estimated effective number of parameters.
Adjustment for the randomization procedure covariate (Table 2, randomization column) decreased
the treatment effects meaning that the effect of studies in which the randomization procedure was
insufficiently described benefitted from this adjustment. A balance within the treatment groups between
studies with sufficient and insufficient description of the randomization procedure would neutralize
this effect, but such balance was not present, especially obvious for golimumab, as the randomization
procedure was insufficiently described in all golimumab studies. Furthermore, this covariate shows
the description of the randomization procedure, however, does not necessarily reflect how the
randomization procedure was performed. We therefore excluded this variable from the multiple
adjustment model.
Th RS model (Table 2, baseline RS column) had the lowest DIC (−50.4) and the largest coefficient
(−0.3%) meaning that this model was the best to describe the data (lowest DIC value) and on the
average changed the outcomes with −0.3%.
Due to the limited number of studies included it would not be meaningful with many covariates
and we therefore also excluded the HAQ score (Table 2, HAQ column), as HAQ is a consequence
of disease activity (Table 2, DAS28 column) and joint destruction (Table 2, baseline RS column),
which accordingly were included together with GC treatment (Table 2, glucocorticoid dose column)
and incomplete outcome (Table 2, incomplete outcome column).
Table 3 shows treatment effects, covariate coefficients, and diagnostic metrics for the random-effects
of the unadjusted consistency model, the RS model and the four-covariate meta-regression model
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(normalized DAS28, normalized RS, normalized GC treatment and incomplete outcome). The fixed-
effect model yielded similar results (not shown). The results are shown as difference in annual percent
point between each of the investigated treatments compared to MTX.
The random-effects models, generally, yielded substantially lower DIC estimates and posterior
mean residual deviances than the corresponding fixed-effects models, suggesting superiority of
the former.
The adjusted models yielded a smaller estimate for σ (0.1; 95% CrI: 0.0, 0.2) than the unadjusted
fit (Table 3, unadjusted model column), indicating that some of the heterogeneity can be explained by
the covariates.
The RS model (Table 3, RS covariate metaregression column) has a lower DIC value (−50.4) than
the four-covariate model (Table 3, 4-covariate metaregression column) (−47.6) indicating that the RS
model is superior.
In general, the effects in the RS model are either improved or unchanged compared with the
unadjusted model, whereas the four-covariate model does not add much to the effects except that the
golimumab outcomes improve.
In the RS model and the four-covariate regression fit, the effect of the standard doses of infliximab
(3 mg/kg/8 weeks ≈ 100 mg/4 weeks), adalimumab (40 mg/2 weeks = 80 mg/4 weeks), etanercept
(50 mg/week = 200 mg/4 weeks) and certolizumab (200 mg/2 weeks = 400 mg/4 weeks) did not differ
significantly from each other, varying from −0.6% to −1.0% per year compared with MTX (Table 3,
values in bold type). These effects were −0.1% to −0.3% better than in the unadjusted model. The effects
of the standard doses of the biosimilars (SB2, CTP, SB4) were identical to their reference drugs (Table 3).
The RS adjustment did not improve the golimumab effects, but the adjustment by four covariates
did render the effect of golimumab closer to the other TNFis (Table 3). Still, this effect remained
statistically inferior (−0.4%). The effects of TNFi mono-therapy (vs. MTX) with standard doses varied
from −0.1% to −0.5% (unadjusted), −0.2% to −0.6% (RS adjusted), and −0.2% to −0.9% (four-covariate
adjusted), except certolizumab 200 mg (−1.3%). TNFi low-dose therapy combined with MTX had effects
like the standard doses of TNFi monotherapy (−0.3% to −0.9%). Moderately high doses (infliximab
6 mg/kg/8 weeks and golimumab 130 mg/4 weeks) did not differ significantly from the standard doses,
but extremely high infliximab doses (infliximab 10mg/kg/8 weeks and 20 mg/kg/8 weeks, 3.5 and
7 times the standard dose) seemed better than the standard doses (−1.1% and −1.4%). A cumulative
rankogram (not shown) showed that the different doses of infliximab (reference drugs and biosimilars)
generally constituted the top treatments judged from their surface under the cumulative ranking
curves [51].
2.6. Additional Analyses
To explore the significance of MTX inadequate response we performed a stratified analysis
comparing inadequate-responder to responder studies and found the following results for standard
TNFi + MTX vs. MTX: Adalimumab: −0.7% vs. −0.4%; certolizumab: −0.7% vs. −0.3%; etanercept:
−1% vs. −0.5%; golimumab: −0.2% vs. −0.1%; infliximab: −1.5% vs. −0.7%.
Some of the effects seemed not to fit into the pattern. The mono-treatment effect of certolizumab
200 mg is unusually large (−1.3%) and so are the differences between sulfasalazine, MTX, and placebo.
Excluding the study of certolizumab 200 mg [41] did not change the remaining effect estimates.
Excluding all sulfasalazine studies did not change the remaining results either.
Finally, we explored fitting a network meta-analysis model to the original RS scale outcome data
with covariates for RSmax and study duration and found qualitatively similar results.
2.7. Inconsistency Checks
The network has nine potentially inconsistent loops (Table 4). Generally, the network and direct
effect estimates agree well with each other, particularly for comparisons with greater support, i.e.,
with many patients in several studies. The node-splitting models did suggest inconsistency in the
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In6MT-In3Mt-Mt loop, seemingly stemming from consistent effect estimates of In3Mt being marginally
(but not significantly) more effective than In6Mt (Table 4, row 7).
Table 4. Results of node-splitting analysis.
Comparison Consistency Effect Direct Effect Indirect Effect p-Value
Et50Mt vs. Et50 −0.2 (−0.5, 0.2) −0.2 (−0.7, 0.2) 0.1 (−0.5, 0.7) 0.42
Mt vs. Et20 0.2 (−0.1, 0.6) 0.3 (−0.1, 0.7) 0.1 (−0.5, 0.8) 0.71
Mt vs. In10Mt 1.0 (0.7, 1.4) 1.5 (0.8, 2.2) 0.8 (0.4, 1.3) 0.12
Mt vs. In3Mt 0.9 (0.6, 1.2) 0.8 (0.5, 1.1) 2.1 (0.7, 3.5) 0.08
Mt vs. In6Mt 0.8 (0.5, 1.2) 0.9 (0.5, 1.3) 0.6 (−0.0, 1.3) 0.40
In6Mt vs. In3Mt 0.1 (−0.2, 0.3) 0.1 (−0.2, 0.3) −1.2 (−2.6, 0.2) 0.08
Pl vs. Mt 0.4 (−0.0, 0.8) 0.3 (−0.1, 0.7) 1.1 (−0.3, 2.6) 0.28
Su vs. Mt −0.7 (−1.2, −0.1) 0.0 (−1.3, 1.4) −0.8 (−1.4, −0.2) 0.28
Su vs. Pl −1.0 (−1.5, −0.6) −1.1 (−1.6, −0.7) −0.3 (−1.7, 1.2) 0.28
Et: etanercept; In: infliximab; Mt: methotrexate; Pl: placebo; Su: sulfasalazine.
2.8. Model Fitness and Comparison
DIC values and posterior mean residual deviances, generally, favoured regression fits over
unadjusted fits, and random-effects models over fixed-effects models.
3. Discussion
In many RA patients, mono-therapy and combination therapy with DMARDs are sufficient to
neutralize inflammatory activity and inhibit radiographic progression [7,8]. Due to costs therapy with
TNFis or other biologics should therefore only be given to RA patients with an insufficient response to
combination therapy with DMARDs [7,8]. Still, to be able to estimate the absolute long-term effect it is
important to define an estimate of the attainable effect of a TNFi, i.e., the total effect compared with
no treatment (i.e., placebo treatment). The present network meta-analysis for the first time defines
this effect to be about −0.9% for TNFi monotherapy and about −1.2% for a TNFi combined with MTX.
However, the success of the attempt to include placebo in the network was limited, as the placebo
studies included were poorly connected in the network and gave rise to borderline inconsistent results,
which must be considered to be non-robust. Future studies with more power are needed to safely
establish these effects.
The analysis also shows that that the effects of different TNFis on radiographic joint destruction in
patients with RA generally are similar and that the effects of biosimilars correspond to the reference
drugs. However, the effect of golimumab in the defined standard dose seemed to be inferior. Although
there may be intraclass differences (high-dose TNFi vs. standard-dose TNFi vs. low-dose TNFi,
and TNFi combination therapy vs. TNFi mono-therapy), the present analysis shows that these
differences are clinically minor compared to the large difference between the TNFi effect and the
placebo effect.
In the stratified analysis of MTX inadequate responders vs. MTX responders, the inadequate
response group had −0.1 to −0.8 percent points better TNFi effects than the MTX responsive group,
probably because the MTX effect is smaller in the inadequate response group. This further emphasizes
that TNFi treatment primarily should be used in patients with insufficient response to MTX and other
DMARDs. This analysis also indicates that, in future analyses, it may be appropriate to separate the
MTX treatment in an adequate response group and an inadequate response group.
No statistically significant inconsistencies were detected (Table 4), but the effect of sulfasalazine,
which was identical with the effect of MTX in the direct comparison, was −0.8% in the indirect
comparison. However, in contrast to the direct comparison, 50% of the MTX studies included in the
indirect comparison included MTX inadequate responders which could explain this inconsistency.
Thus, sulfasalazine was poorly connected to MTX (the central comparator) in the network.
Accordingly, the high effect of monotherapy with certolizumab 200 mg, which had no direct connection
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to MTX in the network, could be explained by its link to the network through sulfasalazine. Paradoxically
infliximab 3 mg/kg was borderline significantly better than infliximab 6 mg/kg in the indirect comparison,
but infliximab 6 mg/kg was investigated in more MTX adequate responders (306) than inadequate
responders (175), whereas Infliximab 3 mg/kg was investigated in fewer MTX adequate responders (480)
than inadequate responders (534). This imbalance could explain the observed paradoxical difference.
In vitro, it has been demonstrated that golimumab has higher affinity, greater capacity to neutralize
TNF and greater conformational stability than infliximab [52]. Such findings have entailed the
assumption that lower doses of golimumab would be equivalent to the defined dose of infliximab.
However, RCTs of golimumab have indicated that the effect of the standard dose of golimumab
was inferior. Our network meta-analysis model without covariates gave results in line with these
findings. Two golimumab studies were performed in MTX adequate responders and two in inadequate
responders and in both groups the effect of golimumab were inferior compared with the other TNFis.
After adjustment for covariates the effect of golimumab approached the effect of the other TNFis,
but did not reach it, indicating that the definition of the standard dose of golimumab may be too low.
This assumption is supported by the finding that the double standard golimumab dose (100 mg/4 weeks)
reached the effect of the other TNFi standard doses.
Previous analyses used process variables, typically ACR response criteria [10,11], which are
sensitive to current treatment. As the TNFis are administered with different time intervals, the outcome
could be influenced by the time of measurement in the dosing cycle. Especially outcomes in patients
treated with infliximab could be sensitive, as the dosing cycle of infliximab is 8 weeks and the evaluation
of the patients typically are performed in the end of the cycle, which could explain the trend towards
inferiority of infliximab [10,11]. The present analysis did not confirm this inferiority, maybe because we
used the essential and approximately irreversible RA outcome, joint destruction, which is insensitive
to short-term treatment variations.
3.1. Limitations
The premise that placebo has no effect may be wrong and, in that case, the true effects may be
even bigger than the present reported effects versus placebo.
A review of RA controlled trials [53] showed that positive study outcome was associated
with publication and timeliness of publication despite registration in a publicly available registry
(Clinicaltrials.gov). A substantial number of RA-RCTs remained unpublished [53]. In their search for
outcomes in unpublished studies, the authors had to rely on abstracts and terms as ‘unsuccessful’ and
‘negative’, which are enough to evaluate whether a study is positive or negative, but not sufficient for a
meta-analysis, which demands detailed results. As the present meta-analysis mainly includes studies
with positive outcomes, it is possible that publication bias may have an impact on the outcome and
that the recorded effects may be higher than the true mean effects.
Linear extrapolation of radiographic scores were used in almost all studies to adjust radiographic
data of participants, who dropped out before the final date of evaluation. We also used this method
to standardize the response data, i.e., imposing a linearity assumption on disease progression.
This assumption is supported by studies showing approximate linearity between disease duration and
radiographic progression of joint destruction [54]. Furthermore, the sensitivity analysis comparing
our standardized outcome with the original RS adjusted for duration and maximal RS showed
similar results.
The GeMTC software package features automated identification of potentially inconsistent
comparisons and subsequent analysis of these by way of node-splitting models for each of the
identified comparisons [55] albeit with fixed vague priors beyond our control. The heterogeneity in the
consistency model and the results of the node-splitting models did not suggest severe inconsistency,
in which case there will not be global inconsistency either.
Heterogeneity and inconsistency are closely related, and we would not expect an inconsistency
model to disclose problems that would undermine our findings.
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3.2. Strengths
We have used WinBUGS models [9] widely recognized as valid in the community to elicit
physiologically meaningful effect sizes of TNF inhibitors, with and without methotrexate.
In conclusion, this analysis shows that the effect of the defined standard doses of TNFis are
close to the achievable efficacy and that only doses 3.5–7 times the standard dose contributed with
a significant additional effect, albeit relatively small from a clinical point of view. Under normal
conditions, such a dose would be unacceptable due to risk of side effects and for economic reasons.
In contrast, below-standard doses of TNFis had effects significantly superior to MTX monotherapy,
and therefore could be sufficient in many individuals with RA. Similarly, the fact that the effect of
biosimilars corresponded to the effect of the reference TNFis suggests a potential for cutting costs of
TNFi use.
4. Materials and Methods
4.1. Types of Studies
Full-length studies published in peer-reviewed journals that were performed according to a
randomized controlled trial design and that scored joint radiographs as the primary or secondary
outcome at two separate time points with a time interval of at least 3 months were included, irrespective
of sample size and publication year.
4.2. Types of Participants
Patients with RA diagnosed according to the 1958 [56] or the 1987 [57] or the 2010 [58] criteria of
the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) were
included. In studies performed before 1959, the stated study definitions of RA were accepted.
4.3. Types of Interventions
All interventions, which included a TNFi either as mono-therapy or in combination with another
drug and compared with a DMARD or different dose of the same drug or biosimilar were selected
for the present analysis. Furthermore, we selected studies with an otherwise untreated placebo-arm,
which through its comparator could be linked to the network of TNFi treatments to be able to indirectly
compare the efficacy of TNFis with an otherwise untreated placebo group.
4.4. Type of Outcome
The outcome was primarily recorded as the change in radiographic score (RS) measured as total
Sharp score or a modification of total Sharp score [12] or Larsen score [54] between baseline and time of
evaluation. To obtain our outcome variable we then standardized these to the percentage of the annual
radiographic progression rate (PARPR) [4] by multiplying the mean score change and its standard
error with a factor K = (100% × 52 weeks)/(RSmax × study duration weeks). This transformation is
justified as radiographic progression and has been shown to be approximately linear [54]
4.5. Search Method for Identification of Studies
All mono-therapy or combination-therapy interventions including small molecule or biologic
disease-modifying antirheumatic drugs were included in the search. These drugs interventions
were 1) DMARDs (leflunomide, MTX, sulfasalazine, injectable gold, chloroquine, cyclosporin A,
D-penicillamine, oral gold, azathioprine, cyclophosphamide, and tacrolimus); 2) glucocorticoids;
3) biologic agents (tumour necrosis factor antagonists (infliximab, etanercept, adalimumab,
certolizumab, golimumab), anti-CD20 antibody (rituximab, ocrelizumab, ofatumumab), T cell
co-stimulation inhibitor (abatacept), interleukin-6 (IL-6) antagonists (tocilizumab, sarilimumab),
IL-1 receptor antagonist (anakinra); and 4) Janus Kinase Inhibitors (tofacitinib, baricitinib). For the
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present study focusing on the effect of TNFis, TNFi studies are selected from this pool together with
studies, which could link the TNFi effect to an otherwise untreated placebo effect.
The search strategy was designed by two authors (LG and NG). We performed the last search
20 April 2019, using the following search strategy in PubMed:
“rheumatoid arthritis and controlled trial and chloroquine OR rheumatoid arthritis and controlled
trial and azathioprine OR rheumatoid arthritis and controlled trial and penicillamine OR rheumatoid
arthritis and controlled trial and cyclophosphamide OR rheumatoid arthritis and controlled trial
and methotrexate OR rheumatoid arthritis and controlled trial and sulfasalazine OR rheumatoid
arthritis and controlled trial and leflunomide OR rheumatoid arthritis and controlled trial and gold OR
rheumatoid arthritis and controlled trial and cyclosporine OR rheumatoid arthritis and controlled trial
and infliximab OR rheumatoid arthritis and controlled trial and etanercept OR rheumatoid arthritis
and controlled trial and adalimumab OR rheumatoid arthritis and controlled trial and certolizumab OR
rheumatoid arthritis and controlled trial and golimumab OR rheumatoid arthritis and controlled trial
and tocilizumab OR rheumatoid arthritis and controlled trial and abatacept OR rheumatoid arthritis
and controlled trial and rituximab OR rheumatoid arthritis and controlled trial and ocrelizumab OR
rheumatoid arthritis and controlled trial and ofatumumab OR rheumatoid arthritis and controlled trial
and glucocorticoid OR rheumatoid arthritis and controlled trial and cortisone OR rheumatoid arthritis
and controlled trial and tofacitinib OR rheumatoid arthritis and controlled trial and baricitinib OR
rheumatoid arthritis and controlled trial and anakinra OR rheumatoid arthritis and controlled trial and
sarilimumab OR rheumatoid arthritis and controlled trial and tacrolimus“.
4.6. Study Selection
Two authors (NG and THG) independently assessed studies for eligibility. Disagreements were
resolved by consensus. Titles were screened, possible abstracts were read, and possible papers were
retrieved. Studies fulfilling the eligibility criteria were included in the meta-analysis. There were no
exclusion criteria for studies fulfilling all inclusion criteria.
4.7. Data Extraction and Management
Two authors (NG/GJ and NG/THG) independently extracted data as published in the original
articles. Disagreements were resolved by discussion between the authors. As a rule, the first publication
of studies with repeated publications of follow-up data was included, but additional publications were
used to provide missing data if possible. Data were recorded on a standardized extraction form using
Excel spreadsheet software from Microsoft. The following baseline variables for each treatment arm
were recorded: mean age, female percentage, percent rheumatoid factor positivity, tender joint count
(TJC), swollen joint count (SJC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), disease
activity score based on 28 joints (DAS28) or 44 joint (DAS44), health assessment questionnaire score
(HAQ) and radiographic score (RS: the sum of erosion score and joint narrowing score). Not all studies
provided data with identical units. We therefore converted some measures from some studies to the
most prevailing unit.
DAS28 conversion: Most of the studies informed about DAS28, but many did not report whether
it was based on 3 or 4 items or on CRP or ESR. However, according to a systematic comparison of
composite measures [59] these 4 DAS28 values are similar at the 50th centile (i.e., the median) and we
therefore recorded the DAS28 values as published in the original articles. A few studies published
DAS44 values (based on 44 joints). These were changed to estimated DAS28 values by means of the
nomogram in the paper by Ranganath et al. [58]. In studies with no report of DAS28 we could estimate
a mean DAS28 from SJC, TJC, and ESR.
Conversion of SJC28 to SJC66: Three of the included studies measured both, and the SJC28
count in the six treatment arms varied between 67% and 74% of the SJC66 count. These numbers
correspond well to the numbers estimated by Fuchs and Pincus [60]. They investigated systematically
the individual participant data from three randomized trials and found these percentages to be 68,
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69, and 83 (mean value 73%). We chose to use this value (73%) as a conversion factor between SJC28
and SJC66.
Conversion of TJC28 to TJC68: Three of the included studies measured both, and the TJC28 count
in the six treatment arms varied between 55% and 64% of the TJC68 count. These numbers correspond
to the numbers estimated by Fuchs and Pincus [60], who found these percentages to be 57, 60, and 71
(mean value 63%). We chose to use this value (63%) as a conversion factor between TJC28 and TJC68.
4.8. Assessment of Risk of Bias in Included Studies
The quality of the studies that were included in our meta-analysis was ensured by requiring
randomization and by using the Cochrane risk of bias tool to assess sequence generation, allocation
concealment, blinding, and incomplete outcome data at the level of the individual study [49]. In addition,
blinding was evaluated at the outcome level. The analysis of incomplete outcome data included
recording of the following features: 1) dropout frequency (total number of patients dropping out after
randomization and first treatment due to lack of effect or side effects, 2) change of treatment strategy
(change of DMARD, addition of DMARD or glucocorticoids, change of placebo to DMARD), and 3) use
of intention-to-treat principle. In addition, we recorded the use glucocorticoids.
4.9. Measure of Treatment Effect
This was defined as the mean difference (MD) between the change in RS from baseline to time of
evaluation. The uncertainty of the observed treatment effect was quantified as the MD standard error.
4.10. Missing Data
We evaluated whether there was bias due to missing studies (publication bias), missing outcomes
(selective reporting bias), or missing individuals (loss of participants during study: attrition bias).
If the SE was not reported it was calculated from a given SD, 95% confidence interval (CI), P value
or t-value, estimated from a figure or imputed from the formula SE (change) = sq. root (SE1sq + SE2sq),
SE1 is SE on R score before intervention and SE2 is SE on R score after intervention.
4.11. Data Synthesis
Outcome and covariates for meta-regression: the extracted outcome estimates varied in three
aspects: the radiographic scoring technique used, and joints included, and follow-up time. To rein these
differences, we derived a conversion factor K = (100% × 52 [weeks])/(RSmax × study duration [weeks]).
Multiplying the RS mean differences and standard errors by K, we obtained annual progressions
in percent and corresponding standard errors [61]. When estimating the absolute treatment effects,
we calculated the weighted mean effect of MTX to follow an N (0.75, 0.082) distribution, arising from a
weighted average of the observed absolute treatment effect of MTX in the included studies.
We extracted data for six study-level covariates for the meta-regressions: average glucocorticoid
dose(mg) used by patients, standardized to prednisolone dose; baseline average HAQ score
(continuous); baseline average DAS28 score (continuous); baseline average total RS (continuous);
description of randomization procedure (sufficient vs. insufficient) assessed on the basis of the
description of sequence generation and allocation concealment; indicator of whether the outcome was
incomplete (no vs. yes or unclear). An outcome was defined as complete if the data-analysis was
performed according to the intention to treat principle under the condition that only data obtained
during the study treatment was used in the final analysis by using the last observation carried forward
or linear extrapolation of the last observation in case of study drug discontinuation. An outcome was
defined as incomplete if only participants completing the study were evaluated, or if intention to
treat data obtained from participants after discontinuation of study treatment and change to another
treatment were included in the data-analysis. All continuous covariates were mean-centred and scaled
to 1 standard deviation.
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4.12. Model Specification and Parameter Estimation
We used only open source software: Analyses and visualization were done with the R statistical
programming language [R Core Team (2018). R: A language and environment for statistical computing.
R Foundation for Statistical Computing, Vienna, Austria. URL available online: https://www.R-project.
org/] version 3.5.1. invoking WinBUGS with the R2WinBUGS Package [62]
We built and ran several fixed-effects and random-effects models with the heterogeneity parameter
σ shared by all treatments: unadjusted consistency model of the treatment effect as difference in annual
progression rate between the treatment in question and MTX [63]; six single-covariate consistency
meta-regression analyses to identity which of the six covariates stated above had substantial impact
on the treatment effects; based on this ‘screening’, we selected the most appropriate covariates to
be included in a multiple regression analysis. The models were linear with Gaussian likelihoods.
We assumed covariate effects to be shared by all treatments, likely rendering the results more useful for
subsequent decision making [64].
To explore the significance of MTX inadequate response, we performed a stratified analysis
comparing inadequate MTX responders vs. MTX responders, using the random-effects multiple
regression model.
We used the R package GeMTC [65] to identify potentially inconsistent loops, and automatically run
the appropriate node-splitting models to gauge the differences between direct, indirect, and collective
network estimates of treatment effects using vague priors akin to those we used in the WinBUGS
models [58].
Unadjusted models had 50,000 sampling iterations and regressions models 100,000 for each of
the four chains, keeping every 20th posterior sample to minimize auto-correlation and ensure precise
estimation. All models ran 50,000 warm-up iterations. To ascertain convergence, we required potential
scale reduction factors ≤ 1.05 [66], overlain posterior densities and mixing chain traces. We gauged
model fitness with the deviance information criterion (DIC) and posterior mean residual deviance:
lower DIC values are preferred, with differences between DICs of 3—5 being meaningful; the posterior
mean residual deviance should be seen in light of the number of data points and should not go up
when more parameters are added. We used vague N(0, 1002) priors for nuisance parameters, treatment
effects, and covariate coefficients [63].
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